ArticleHealth policy and technology2022
COVID-19 and counterfeit vaccines: Global implications, new challenges and opportunities.
Article in Health policy and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Convolutional neural network analysis of cervical CT images: classification of Kikuchi disease, lymphoma, lymphadenitis, and tuberculosis.Biomedical engineering online · 2026Article
- [Substandard and falsified medical products: 25 years of successful network collaboration among regulatory authorities in the AmericasProdutos médicos de qualidade inferior e falsificados: 25 anos de colaboração bem-sucedida em rede entre autoridades reguladoras da Região das Américas].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review.Journal of pharmaceutical policy and practice · 2025Review
- Supply chain traceability and counterfeit detection of COVID-19 vaccines using novel blockchain-basedExpert systems with applications · 2023Article
- Ensuring vaccine safety: Case studies of falsified influenza vaccines detected in Brazil.Vaccine: X · 2023Article
- Greening aviation in era of COVID-19: Towards conceptualizing and operationalizing decarbonization.Journal of environmental management · 2023Article
- [Regulation of the online sale of medical products: experiences and strategies for Latin AmericaRegulamentação da venda de produtos médicos pela internet: experiências e estratégias para a América Latina].Revista panamericana de salud publica = Pan American journal of public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research note (RN) examines the drivers and consequences of proliferation of counterfeit (substandard and falsified) COVID-19 vaccines. An integrated framework was advanced which sheds light on the domestic contributory factors such a desperation by citizens to "return to normalcy", institutional impediments, minimum standards of enforcement of laws related to intellectual property rights and lack of access to vaccines in tandem with international environmental drivers such as the growth of online pharmacies, international market intermediaries and vaccine nationalism. Consequently, counterfeit COVID-19 vaccines appear to serve as a disincentive to innovation and investment in research and development activities. The analysis highlights health-related consequences including providing a false sense of security against a dangerous virus and potentially loss of confidence in reliable medicines. This analysis led to the generation of some vital socio-economic implications for public policy and enterprises, which are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.